Identification and characterization of Prothionamide degradation impurities by mass spectrometry, NMR spectroscopy, and ultra high performance liquid chromatography method development
- PMID: 33733566
- DOI: 10.1002/jssc.202100050
Identification and characterization of Prothionamide degradation impurities by mass spectrometry, NMR spectroscopy, and ultra high performance liquid chromatography method development
Abstract
Stability-indicating and liquid chromatography-mass spectrometry compatible ultra high performance liquid chromatography method was developed for the degradation and drug substances related impurities of Prothionamide. Forced degradation of Prothionamide was carried out under acidic, basic, thermal, oxidative, and photolytic stress conditions. The impurities separation was achieved on Acquity UPLC BEH-C18 (50 mm × 2.1 mm, 1.7 μm) with the mobile phase of 10 mm ammonium acetate pH 6.0 and Acetonitrile in a time gradient mode. Related substances by ultra-performance liquid chromatography method was validated according to ICH tripartite guidelines. Degradation products were isolated by Column chromatography and characterized by liquid chromatography-mass spectrometry, 1 H, and 13 C nuclear magnetic resonance spectroscopy. The developed related substances method showed adequate specificity, sensitivity, accuracy, linearity (0.4-1.5 μg/mL), precision, and robustness in line with ICH tripartite guidelines for validation of analytical procedures. Limits of detection and quantitation were 0.1 and 0.4 μg/mL, respectively, for Prothionamide and all the impurities. The method was found to be linear with a correlation coefficient > 0.99, precise (%RSD < 5.0), robust and accurate (%recovery 85-115%).
Keywords: degradation impurities; method validation; prothionamide; stress conditions; structural elucidation.
© 2021 Wiley-VCH GmbH.
References
REFERENCES
-
- Prothionamide. Tuberculosis. 2008, 88(2), 139-40.
-
- Feng W., Robert L., Gulcin G., Lynn G., Gurdyal S., William R., Jacobs Jr., James C., Mechanism of thioamide drug action against tuberculosis and leprosy. J. Exp. Med. 2007, 204, 73-8.
-
- Thee S., Garcia P., Donald P., Hesseling A., Schaaf H., A review of the use of ethionamide and prothionamide in childhood tuberculosis. Tuberculosis. 2016, 97, 126-36.
-
- Fajardo T., Guinto R., Cellona R., Abalos R., Dela C., Gelber R., A clinical trial of ethionamide and prothionamide for treatment of lepromatous leprosy. Am. J. Trop. Med. Hyg. 2006, 74, 457-61.
-
- Venkatesan K., Clinical pharmacokinetic considerations in the treatment of patients with leprosy. Clin. Pharmacokinet. 1989, 16, 365-86.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources